Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo.
Durham, T.B., Toth, J.L., Klimkowski, V.J., Cao, J.X., Siesky, A.M., Alexander-Chacko, J., Wu, G.Y., Dixon, J.T., McGee, J.E., Wang, Y., Guo, S.Y., Cavitt, R.N., Schindler, J., Thibodeaux, S.J., Calvert, N.A., Coghlan, M.J., Sindelar, D.K., Christe, M., Kiselyov, V.V., Michael, M.D., Sloop, K.W.(2015) J Biol Chem 290: 20044-20059
- PubMed: 26085101 
- DOI: 10.1074/jbc.M115.638205
- Primary Citation of Related Structures:  
4PFC, 4PF7, 4PF9 - PubMed Abstract: 
Insulin-degrading enzyme (IDE, insulysin) is the best characterized catabolic enzyme implicated in proteolysis of insulin. Recently, a peptide inhibitor of IDE has been shown to affect levels of insulin, amylin, and glucagon in vivo. However, IDE(-/-) mice display variable phenotypes relating to fasting plasma insulin levels, glucose tolerance, and insulin sensitivity depending on the cohort and age of animals ...